Vanguard Capital Management
LGND icon

Vanguard Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Vanguard Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275M Buy
870,950
+22,861
+3% +$5.39M 0.01% 955
2026
Q1 		$169M Buy
+848,089
New +$168M ﹤0.01% 1164

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Vanguard Capital Management's LGND Position: Q2 2026 in Review

Vanguard Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 2.7% in Q2 2026, buying an estimated $5.39M and bringing the position to 870,950 shares worth $275M. The position accounts for 0.01% of the portfolio, ranked #955.

Vanguard Capital Management first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 408 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Vanguard Capital Management held 870,950 shares of Ligand Pharmaceuticals worth $275M as of Q2 2026.
  • Vanguard Capital Management bought 22,861 Ligand Pharmaceuticals shares in Q2 2026, an estimated $5.39M.
  • Ligand Pharmaceuticals made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #955 holding.
  • Vanguard Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 408 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.